Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI) (ESTATE)

This study has been terminated.
(Slower than anticipated enrollment for pilot study.)
Information provided by (Responsible Party):
Indiana University ( Indiana University School of Medicine ) Identifier:
First received: September 17, 2009
Last updated: September 3, 2014
Last verified: September 2014

This research study plans to evaluate the use of atorvastatin in patients with coronary artery disease given immediately before PCI and whether it will decrease the amount of heart damage after PCI.

Condition Intervention
Coronary Artery Disease
Drug: Atorvastatin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After PCI

Resource links provided by NLM:

Further study details as provided by Indiana University:

Primary Outcome Measures:
  • periprocedural myonecrosis [ Time Frame: 16-24 hours post PCI ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: November 2008
Study Completion Date: August 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: No atorvastatin
Patients do not receive Atorvastatin prior to PCI in cath lab
Experimental: atorvastatin
Atorvastatin 80mg po given prior to PCI in cath lab
Drug: Atorvastatin
Atorvastatin 80mg po given one time before PCI in cath lab.


Ages Eligible for Study:   21 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients undergoing revascularization for significant coronary artery disease
  • age range 21-85 years

Exclusion Criteria:

  • non-STEMI, STEMI
  • cancer
  • renal failure with creatinine>3.0mg/dl
  • liver cirrhosis
  • lymphoproliferative disorder
  • pregnancy
  • thrombocytopenia<150'000
  • coagulopathy (INR>1.5)
  • abnormal liver function tests
  • illicit drug use
  • history of statin intolerance
  • history of rhabdomyolysis
  • planned use of Glycoprotein IIb/IIIa inhibitors during PCI
  • current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00979940

United States, Indiana
Methodist Hospital
Indianapolis, Indiana, United States, 46202
Wishard Hospital
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University School of Medicine
Principal Investigator: Rolf Kreutz, MD Indiana University School of Medicine
  More Information

No publications provided

Responsible Party: Indiana University ( Indiana University School of Medicine ) Identifier: NCT00979940     History of Changes
Other Study ID Numbers: 0712-15, 1470
Study First Received: September 17, 2009
Last Updated: September 3, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Indiana University:
percutaneous intervention
periprocedural myonecrosis

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on February 27, 2015